You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

trastuzumab

Showing 76 - 100 of 1,505
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HER2 Positive Early Breast Cancer Trial in Shanghai (Docetaxel, carboplatin, Trastuzumab)

Recruiting
  • HER2 Positive Early Breast Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center Shanghai, China, 200032
Jun 6, 2023

HER2-positive Breast Cancer, Metastatic Breast Cancer Trial in Shanghai (Trastuzumab plus chemo, Trastuzumab in combination with

Recruiting
  • HER2-positive Breast Cancer
  • Metastatic Breast Cancer
  • Trastuzumab plus chemotherapy
  • Trastuzumab in combination with pyrotinib plus chemotherapy
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Apr 20, 2022

Breast Cancer Trial in Houston (Durvalumab, Trastuzumab, Pertuzumab)

Recruiting
  • Breast Cancer
  • Houston, Texas
    Houston Methodist Cancer Center
Aug 5, 2022

Breast Cancer Trial in Chengdu (Pyrotinib combined with albumin-bound paclitaxel and trastuzumab)

Recruiting
  • Breast Cancer
  • Pyrotinib combined with albumin-bound paclitaxel and trastuzumab
  • Chengdu, Chengdu, Sichuan, China, China
    West China Hospital, Sichuan University
Oct 7, 2022

Breast Cancer Trial in Boston (T-DM1, Pembrolizumab)

Active, not recruiting
  • Breast Cancer
  • Boston, Massachusetts
  • +1 more
Jul 25, 2022

HER2-positive Breast Cancer Trial in Tampa (biological, drug, procedure)

Recruiting
  • HER2-positive Breast Cancer
  • HER-2 pulsed DC1
  • +4 more
  • Tampa, Florida
    Moffitt Cancer Center
Oct 6, 2022

Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7 Trial in United States

Recruiting
  • Breast Adenocarcinoma
  • +7 more
  • Multi-epitope HER2 Peptide Vaccine TPIV100
  • +5 more
  • Scottsdale, Arizona
  • +26 more
Aug 17, 2022

Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8 Trial

Recruiting
  • Anatomic Stage I Breast Cancer AJCC v8
  • +19 more
  • pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 1, 2022

Advanced Gastric Adenocarcinoma Trial in Henan (camrelizumab)

Recruiting
  • Advanced Gastric Adenocarcinoma
  • Henan, China
    Henan Tumor Hospital
Oct 13, 2022

Esophageal Cancer, Esophageal Adenocarcinoma Trial in Amsterdam (Trastuzumab, Pertuzumab, Paclitaxel)

Recruiting
  • Esophageal Cancer
  • Esophageal Adenocarcinoma
  • Trastuzumab
  • +3 more
  • Amsterdam, Netherlands
    Academic Medical Center
Jun 18, 2022

Oncology, Infusion Reaction Trial (Nivolumab, Pembrolizumab, Ipilimumab)

Not yet recruiting
  • Oncology
  • Infusion Reaction
  • (no location specified)
Sep 8, 2023

Breast Tumors Trial in Saint Louis (Doxorubicin, Trastuzumab, Cyclophosphamide)

Terminated
Has Results
  • Breast Neoplasms
  • Saint Louis, Missouri
    Washington University School of Medicine
Oct 31, 2022

Breast Cancer Trial (Tucatinib, Eribulin, Trastuzumab)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
Jul 12, 2022

HER2-positive Breast Cancer, Operable Breast Cancer Trial in France (Trastuzumab + Paclitaxel, Pegfilgrastim)

Recruiting
  • HER2-positive Breast Cancer
  • Operable Breast Cancer
  • Avignon, France
  • +8 more
Jan 9, 2023

Anatomic Stage IV Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Metastatic Breast Carcinoma Trial in United States

Withdrawn
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +3 more
  • Yuma, Arizona
  • +5 more
May 25, 2022

Salivary Gland Cancer, HER2 Gene Mutation Trial in Boston (Ado-trastuzumab (T) emtansine (T-DM1), Standard of Care Radiotherapy,

Recruiting
  • Salivary Gland Cancer
  • HER2 Gene Mutation
  • Ado-trastuzumab (T) emtansine (T-DM1)
  • +2 more
  • Boston, Massachusetts
  • +1 more
Jan 2, 2023

HER2-positive Advanced Breast Cancer Trial (DP303c, Trastuzumab, Vinorelbine Tartrate)

Not yet recruiting
  • HER2-positive Advanced Breast Cancer
  • (no location specified)
Jun 4, 2023

Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8

Recruiting
  • Anatomic Stage II Breast Cancer AJCC v8
  • +19 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
May 11, 2022

HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Metastatic Breast Cancer Trial in Germany, Spain,

Recruiting
  • HER2-positive Breast Cancer
  • +4 more
  • Essen, Germany
  • +5 more
Nov 15, 2022

Adenocarcinoma of the Rectum, Locally Advanced Rectal Adenocarcinoma, Rectal Adenocarcinoma Trial in United States (Trastuzumab,

Recruiting
  • Adenocarcinoma of the Rectum
  • +4 more
  • Basking Ridge, New Jersey
  • +6 more
Jan 3, 2023

Gastric Cancer Trial in Philadelphia (Neratinib Pill, Fam-Trastuzumab Deruxtecan-Nxki (TDxD))

Suspended
  • Gastric Cancer
  • Neratinib Pill
  • Fam-Trastuzumab Deruxtecan-Nxki (TDxD)
  • Philadelphia, Pennsylvania
    Fox Chase Cancer Center
Jul 6, 2022

HER2-positive Breast Cancer, Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7 Trial in San Francisco (Neratinib,

Completed
  • HER2-positive Breast Cancer
  • +8 more
  • San Francisco, California
    University of California, San Francisco
Jan 6, 2023

HER2-positive Breast Cancer, LMD Trial (Tucatinib 150 MG, Trastuzumab, Capecitabine)

Not yet recruiting
  • HER2-positive Breast Cancer
  • LMD
  • Tucatinib 150 MG
  • +3 more
  • (no location specified)
Aug 24, 2023

Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, HER2-positive Gastric Cancer Trial in China

Not yet recruiting
  • Adenocarcinoma of the Stomach
  • +2 more
  • Hangzhou, Zhejiang, China
  • +7 more
Feb 7, 2023

First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer Trial (KN026, HB1801, Pertuzumab)

Not yet recruiting
  • First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
  • (no location specified)
Apr 20, 2023